References
Cresta S, Grasselli G, Mansutti M, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 2004; 15: 433–9
Hogberg T, Glimelius B, Nygren P, et al. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001; 40: 340–60
Kimby E, Brandt L, Nygren P, et al. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia. Acta Oncologica 2001; 40: 224–30
Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145–53
Sparano JA, O’Neill A, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: eastern cooperative oncology group study E1196. J Clin Oncol 2000; 18: 2369–77
To H, Kikuchi A, Tsuruoka S, et al. Time-dependent nephrotoxicity associated with daily administration of cisplatin in mice. J Pharm Pharmacol 2000; 52: 1499–504
Ohdo S, Koyanagi S, Suyama H, et al. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 2001; 7: 356–60
Matsunaga N, Nakamura N, Yoneda N, et al. Influence of feeding schedule on 24-hr rhythm of hepatotoxicity induced by acetaminophen in mice. J Pharmacol Exp Ther 2004; 311: 594–600
Ohdo S. Changes in toxicity and effectiveness with timing of drug administration. Drug Saf 2003, 26: 999–1010
Burns ER. Circadian biological time influences the effect adriamycin has on DNA synthesis in mouse bone marrow, ileum and tongue but not Ehrlich ascites carcinoma. Oncology 1985; 42: 384–7
Sothern RB, Levi F, Haus E, et al. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst 1989; 81: 135–45
Granda TG, Filipski E, D’Attino RM, et al. Experimental chronotherapy of mouse breast adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res 2001; 61: 1996–2001
To H, Ohdo S, Shin M, et al. Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 2003; 55: 803–10
Canal P, Aqall A, de Forni M, et al. Chronopharmacokinetics of doxorubicin in patients with breast cancer. Eur J Clin Pharmacol 1991; 40: 287–91
Hrushesky WJ. Circadian timing of cancer chemotherapy. Science 1985; 228: 73–5
Barrett RJ, Blessing JA, Homesley HD, et al. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993; 16: 494–6
Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869–79
von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7
Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19: 314–21
Labrecque G, Blelanger PM, Dore F, et al. 24 hour variations in the distribution of labeled microspheres to the intestine, liver and kidneys. Ann Rev Chronopharmacol 1988; 5: 445–8
Lemmer B, Nold G. Circadian changes in estimated hepatic blood flow in healthy subjects. Br J Clin Pharmacol 1991; 32: 627–9
Acknowledgements
There was no external funding for this study. The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
To, H., Saito, T., Shigehiro, O. et al. Doxorubicin Chronotherapy in Japanese Outpatients with Breast Cancer. Drugs R D 6, 101–107 (2005). https://doi.org/10.2165/00126839-200506020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200506020-00005